Skip to main content
Clinical Trials/TCTR20230214003
TCTR20230214003
Recruiting
Phase 4

The study to evaluate the efficacy and safety of Polynucleotide for Periorbital Rejuvenation in Thailand

SW HEALTHCARE CO.,LTD0 sites25 target enrollmentFebruary 14, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Healthy
Sponsor
SW HEALTHCARE CO.,LTD
Enrollment
25
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 14, 2023
End Date
October 16, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
SW HEALTHCARE CO.,LTD

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 25\-55 years old
  • 2\. Both male and female
  • 3\. Grade 1\-5 wrinkle at periorbital by Wrinkle Assessment Scale of periorbital lines

Exclusion Criteria

  • 1\. Subjects who are pregnant
  • 2\. Subjects who had history of low platelet, coagulopathy or taking medicine of antocoagulant drug like warfarin
  • 3\. Subjects who has dermatits, wound or infection at treatment area
  • 4\. Subjects who allergy to anesthesia cream
  • 5\. Subjects who taken oral or injection contraceptive pills
  • 6\. Subjects who had history of laser, filler and botox at treatment area within 6 months before arrived the project
  • 7\. Subjects who had history of keloid or hypertrophic scar
  • 8\. Subjects who had history of psychitic disease

Outcomes

Primary Outcomes

Not specified

Similar Trials